Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Jefferies biotech analyst to hold an analyst/industry conference call » 15:33
06/02/20
06/02
15:33
06/02/20
15:33
MRNA

Moderna

$59.02 /

-3.15 (-5.07%)

, PFE

Pfizer

$36.02 /

+0.55 (+1.55%)

, SNY

Sanofi

$49.71 /

+0.185 (+0.37%)

, AZN

AstraZeneca

$54.41 /

-0.81 (-1.47%)

, JNJ

Johnson & Johnson

$147.24 /

+0.09 (+0.06%)

, MRK

Merck

$80.42 /

+0.85 (+1.07%)

, INO

Inovio

$14.29 /

-0.58 (-3.90%)

, NVAX

Novavax

$50.00 /

-2.83 (-5.36%)

, BNTX

BioNTech

$51.34 /

-0.91 (-1.74%)

Biotech Analyst Yee,…

Biotech Analyst Yee, along with expert virologist Dr. Curriel, discuss recent COVID-19 vaccine data from Moderna and CanSino, as well as upcoming vaccine results for Pfizer/BioNtech (PFE/BNTX), AstraZeneca (AZN), Inovio (INO) and Johnson & Johnson (JNJ) on an Analyst/Industry conference call to be held on June 8 at 10 am.

ShowHide Related Items >><<
SNY Sanofi
$49.71 /

+0.185 (+0.37%)

PFE Pfizer
$36.02 /

+0.55 (+1.55%)

NVAX Novavax
$50.00 /

-2.83 (-5.36%)

MRNA Moderna
$59.02 /

-3.15 (-5.07%)

MRK Merck
$80.42 /

+0.85 (+1.07%)

JNJ Johnson & Johnson
$147.24 /

+0.09 (+0.06%)

INO Inovio
$14.29 /

-0.58 (-3.90%)

BNTX BioNTech
$51.34 /

-0.91 (-1.74%)

AZN AstraZeneca
$54.41 /

-0.81 (-1.47%)

MRNA Moderna
$59.02 /

-3.15 (-5.07%)

06/02/20 Piper Sandler
Piper reiterates Overweight rating, $100 target for Moderna after Science Day
06/02/20 BofA
Moderna price target lowered to $75 from $80 at BofA
06/01/20 Goldman Sachs
Goldman keeps $105 target after Moderna COVID vaccine moves to Phase 2
05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
PFE Pfizer
$36.02 /

+0.55 (+1.55%)

06/01/20 Morgan Stanley
Lilly trial has higher risk and reward after Pfizer failure, says Morgan Stanley
06/01/20 Barclays
Pfizer price target lowered to $35 from $37 at Barclays
05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
SNY Sanofi
$49.71 /

+0.185 (+0.37%)

05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/27/20 Citi
BioMarin a good takeout candidate, but not by Sanofi, says Citi
05/26/20 UBS
Sanofi price target lowered to EUR 101 from EUR 103 at UBS
05/26/20 Piper Sandler
Piper remains buyer of Regeneron, ups target to $630 on buyback accretion
AZN AstraZeneca
$54.41 /

-0.81 (-1.47%)

06/01/20 Piper Sandler
Aveo's tivozanib could launch in U.S. next year, says Piper Sandler
05/29/20 Guggenheim
AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim
05/14/20 Evercore ISI
Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine
05/06/20 Morgan Stanley
AstraZeneca price target raised to 8,630 GBp from 8,600 GBp at Morgan Stanley
JNJ Johnson & Johnson
$147.24 /

+0.09 (+0.06%)

05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/29/20 Barclays
Johnson & Johnson price target raised to $182 from $173 at Barclays
MRK Merck
$80.42 /

+0.85 (+1.07%)

06/02/20 JPMorgan
JPMorgan positions for second half with three picks in Major Pharma
05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
INO Inovio
$14.29 /

-0.58 (-3.90%)

06/01/20 Piper Sandler
Context 'may be necessary' for Inovio's INO-5401 GBM update, says Piper Sandler
05/21/20 Benchmark
Inovio initiated with a Buy at Benchmark
05/20/20 Roth Capital
Most of Inovio COVID-19 vaccine data 'over two months old,' says Roth Capital
05/20/20 Piper Sandler
Piper Sandler stays Neutral on Inovio, offers a 'little perspective' on vaccine
NVAX Novavax
$50.00 /

-2.83 (-5.36%)

05/26/20 B. Riley FBR
Novavax has become a leading COVID vaccine candidate, says B. Riley FBR
05/18/20 B. Riley FBR
Novavax price target raised to $53 from $43 at B. Riley FBR
05/14/20 Ladenburg
Novavax price target raised to $50 from $38 at Ladenburg
05/12/20 B. Riley FBR
Novavax price target raised to $43 from $29 at B. Riley FBR
BNTX BioNTech
$51.34 /

-0.91 (-1.74%)

04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/13/20 H.C. Wainwright
BioNTech price target raised to $48 from $30 at H.C. Wainwright
SNY Sanofi
$49.71 /

+0.185 (+0.37%)

PFE Pfizer
$36.02 /

+0.55 (+1.55%)

NVAX Novavax
$50.00 /

-2.83 (-5.36%)

MRNA Moderna
$59.02 /

-3.15 (-5.07%)

MRK Merck
$80.42 /

+0.85 (+1.07%)

JNJ Johnson & Johnson
$147.24 /

+0.09 (+0.06%)

INO Inovio
$14.29 /

-0.58 (-3.90%)

BNTX BioNTech
$51.34 /

-0.91 (-1.74%)

AZN AstraZeneca
$54.41 /

-0.81 (-1.47%)

SNY Sanofi
$49.71 /

+0.185 (+0.37%)

PFE Pfizer
$36.02 /

+0.55 (+1.55%)

NVAX Novavax
$50.00 /

-2.83 (-5.36%)

MRNA Moderna
$59.02 /

-3.15 (-5.07%)

MRK Merck
$80.42 /

+0.85 (+1.07%)

JNJ Johnson & Johnson
$147.24 /

+0.09 (+0.06%)

INO Inovio
$14.29 /

-0.58 (-3.90%)

AZN AstraZeneca
$54.41 /

-0.81 (-1.47%)

SNY Sanofi
$49.71 /

+0.185 (+0.37%)

PFE Pfizer
$36.02 /

+0.55 (+1.55%)

NVAX Novavax
$50.00 /

-2.83 (-5.36%)

MRNA Moderna
$59.02 /

-3.15 (-5.07%)

MRK Merck
$80.42 /

+0.85 (+1.07%)

JNJ Johnson & Johnson
$147.24 /

+0.09 (+0.06%)

INO Inovio
$14.29 /

-0.58 (-3.90%)

BNTX BioNTech
$51.34 /

-0.91 (-1.74%)

AZN AstraZeneca
$54.41 /

-0.81 (-1.47%)

SNY Sanofi
$49.71 /

+0.185 (+0.37%)

PFE Pfizer
$36.02 /

+0.55 (+1.55%)

NVAX Novavax
$50.00 /

-2.83 (-5.36%)

MRNA Moderna
$59.02 /

-3.15 (-5.07%)

MRK Merck
$80.42 /

+0.85 (+1.07%)

JNJ Johnson & Johnson
$147.24 /

+0.09 (+0.06%)

INO Inovio
$14.29 /

-0.58 (-3.90%)

BNTX BioNTech
$51.34 /

-0.91 (-1.74%)

AZN AstraZeneca
$54.41 /

-0.81 (-1.47%)

Recommendations
JPMorgan positions for second half with three picks in Major Pharma » 08:36
06/02/20
06/02
08:36
06/02/20
08:36
ABBV

AbbVie

$90.71 /

-2.07 (-2.23%)

, LLY

Eli Lilly

$152.30 /

-0.84 (-0.55%)

, MRK

Merck

$79.57 /

-1.28 (-1.58%)

JPMorgan analyst Chris…

JPMorgan analyst Chris Schott names AbbVie (ABBV), Eli Lilly (LLY) and Merck (MRK) his top three picks in U.S. Major Pharma into the second half of 2020. The group has moderately outperformed the broader market year-to-date but has underperformed over the last month with cyclicals sectors driving outperformance relative to Pharma and other more defensive sectors, Schott tells investors in a research note. Despite these recent moves, fundamentals remain healthy with the recent uptick in physician visits/prescriptions trends suggesting little impact to the sector from COVID, adds the analyst. Schott sees an attractive longer-term setup "with the sector in the midst of a solid new product cycle" and drug price reform headlines receding.

ShowHide Related Items >><<
MRK Merck
$79.57 /

-1.28 (-1.58%)

LLY Eli Lilly
$152.30 /

-0.84 (-0.55%)

ABBV AbbVie
$90.71 /

-2.07 (-2.23%)

ABBV AbbVie
$90.71 /

-2.07 (-2.23%)

06/02/20 Argus
AbbVie upgraded to Buy from Hold at Argus
06/02/20 Argus
AbbVie upgraded to Buy from Hold at Argus
05/22/20 Piper Sandler
Growth of Biohaven's Nurtec continues to beat AbbVie's Ubrelvy, says Piper
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
LLY Eli Lilly
$152.30 /

-0.84 (-0.55%)

06/01/20 Morgan Stanley
Lilly trial has higher risk and reward after Pfizer failure, says Morgan Stanley
05/29/20 Raymond James
Blueprint approval for pralsetinib could come before PDUFA, says Raymond James
04/24/20 Cantor Fitzgerald
Eli Lilly price target raised to $185 from $156 at Cantor Fitzgerald
04/24/20 Mizuho
Eli Lilly price target raised to $155 from $148 at Mizuho
MRK Merck
$79.57 /

-1.28 (-1.58%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
MRK Merck
$79.57 /

-1.28 (-1.58%)

LLY Eli Lilly
$152.30 /

-0.84 (-0.55%)

ABBV AbbVie
$90.71 /

-2.07 (-2.23%)

MRK Merck
$79.57 /

-1.28 (-1.58%)

LLY Eli Lilly
$152.30 /

-0.84 (-0.55%)

ABBV AbbVie
$90.71 /

-2.07 (-2.23%)

MRK Merck
$79.57 /

-1.28 (-1.58%)

LLY Eli Lilly
$152.30 /

-0.84 (-0.55%)

ABBV AbbVie
$90.71 /

-2.07 (-2.23%)

MRK Merck
$79.57 /

-1.28 (-1.58%)

ABBV AbbVie
$90.71 /

-2.07 (-2.23%)

Monday
Hot Stocks
Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment » 10:53
06/01/20
06/01
10:53
06/01/20
10:53
MRK

Merck

$79.83 /

-1.02 (-1.26%)

Junshi Biosciences…

Junshi Biosciences announced their collaboration on a clinical trial program designed to investigate the efficacy and safety of anti-PD-1 mAb toripalimab in combination with Cetuximab as a treatment for recurrent and/or metastatic squamous cell carcinomas of the head and neck in China. Cetuximab is an IgG1 monoclonal antibody that specifically targets the EGFR. The inhibition of EGFR blocks the processes involved in tumor cell growth and progression. Cetuximab is also a potent inducer of antibody-dependent cell mediated cytotoxicity, inducing antitumor immune effect. In February 2020, Cetuximab was granted an approval by China's National Medical Products Administration for the first-line treatment of R/M SCCHN using a combination chemotherapy regimen. Developed by Junshi Biosciences, toripalimab is the first domestically marketed PD-1 monoclonal antibody in China. Anti-PD-1 mAb is an immunotherapy that can activate and direct the body's own immune system to attack tumor cells by inhibiting the PD-1 pathway. Over 30 toripalimab mono and combo clinical trials have been conducted globally for more than 10 tumor types, and show encouraging anti-tumor outcomes. Cetuximab and PD-1 inhibitors are believed to have a synergistic mechanism of action in SCCHN treatment. Preliminary data of early-phase studies have shown promising results from combining immune checkpoint inhibitors with cetuximab.

ShowHide Related Items >><<
MRK Merck
$79.83 /

-1.02 (-1.26%)

MRK Merck
$79.83 /

-1.02 (-1.26%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
MRK Merck
$79.83 /

-1.02 (-1.26%)

MRK Merck
$79.83 /

-1.02 (-1.26%)

MRK Merck
$79.83 /

-1.02 (-1.26%)

MRK Merck
$79.83 /

-1.02 (-1.26%)

Periodicals
Merck CEO to CNBC: George Floyd 'could be me' » 08:54
06/01/20
06/01
08:54
06/01/20
08:54
MRK

Merck

$80.85 /

+1.83 (+2.32%)

Merck CEO Ken Frazier…

Merck CEO Ken Frazier said that George Floyd, an unarmed black man who died at the hands of Minneapolis police, could have been him, telling CNBC's "Squawk Box" that "What the African American community sees in that video tape is that this African American man, who could be me or any other African American man, is being treated as less than human." Reference Link

ShowHide Related Items >><<
MRK Merck
$80.85 /

+1.83 (+2.32%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
MRK Merck
$80.85 /

+1.83 (+2.32%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

Hot Stocks
Merck, AstraZeneca: LYNPARZA receives positive opinion from EU CHMP » 06:47
06/01/20
06/01
06:47
06/01/20
06:47
MRK

Merck

$80.85 /

+1.83 (+2.32%)

, AZN

AstraZeneca

$54.60 /

+1.1 (+2.06%)

AstraZeneca (AZN) and…

AstraZeneca (AZN) and Merck (MRK) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending LYNPARZA for approval as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2 mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. The CHMP based its positive opinion on results from the Phase 3 POLO trial, which were previously published in The New England Journal of Medicine. The trial demonstrated LYNPARZA nearly doubled the time patients with gBRCAm metastatic pancreatic cancer lived without disease progression or death to a median of 7.4 months vs. 3.8 months on placebo.

ShowHide Related Items >><<
MRK Merck
$80.85 /

+1.83 (+2.32%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

05/29/20 Guggenheim
AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim
05/14/20 Evercore ISI
Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine
05/06/20 Morgan Stanley
AstraZeneca price target raised to 8,630 GBp from 8,600 GBp at Morgan Stanley
05/04/20 Citi
Citi opens 'positive catalyst watch' on AstraZeneca
MRK Merck
$80.85 /

+1.83 (+2.32%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

Sunday
Hot Stocks
Immutep reports first results from INSIGHT-004 study » 20:11
05/31/20
05/31
20:11
05/31/20
20:11
IMMP

Immutep

$1.25 /

+0.005 (+0.40%)

, MRK

Merck

$80.85 /

+1.83 (+2.32%)

, PFE

Pfizer

$38.14 /

-0.03 (-0.08%)

Immutep (IMMP) has…

Immutep (IMMP) has reported first interim data from its ongoing INSIGHT-004 Phase I clinical trial. The study is a phase I trial evaluating the combination of Immutep's lead product candidate, eftilagimod alpha with avelumab, a human anti-PD-L1 antibody, in 12 patients with solid cancers. Avelumab is co-developed and co-commercialized by Merck (MRK) KGaA, Darmstadt, Germany and Pfizer (PFE). The data was reported in a short talk poster presentation at the virtual event for the 2020 American Society of Clinical Oncology's Annual Meeting. INSIGHT-004 is the fourth arm of the investigator-initiated INSIGHT trial which is being conducted by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt. It is being conducted under Immutep's collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer, and is evaluating the safety, tolerability and recommended Phase II dose of efti when given in combination with avelumab. Patients in cohort 1 receive 6mg doses of efti every two weeks with the standard dose of avelumab, while patients in cohort 2 receive a higher dose of efti, 30mg, with avelumab. INSIGHT-004 reached full recruitment in April 2020 and has recruited patients in different solid tumors, primarily with gastrointestinal indications. It is the first combination trial of an approved and marketed anti-PD-L1 drug and efti. Salah-Eddin Al-Batran, INSIGHT-004 trial investigator and Director of Oncology at IKF said: "It is good to see a number of patients are responding to the combination therapy of efti and avelumab, particularly as three patients in cohort 2 are still very early on in their treatment and haven't yet been assessed. INSIGHT-004 is progressing well and we are pleased that efti continues to be safe and well tolerated by patients. These patients typically are heavily pretreated and do not have any good therapy options."

ShowHide Related Items >><<
PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

IMMP Immutep
$1.25 /

+0.005 (+0.40%)

IMMP Immutep
$1.25 /

+0.005 (+0.40%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
PFE Pfizer
$38.14 /

-0.03 (-0.08%)

05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

Hot Stocks
Immutep announces data from Phase II TACTI-002 study » 20:08
05/31/20
05/31
20:08
05/31/20
20:08
IMMP

Immutep

$1.25 /

+0.005 (+0.40%)

, MRK

Merck

$80.85 /

+1.83 (+2.32%)

Immutep (IMMP) announced…

Immutep (IMMP) announced new interim data from its ongoing Phase II TACTI-002 study. This data relates to the cut-off date of 4 May 2020 and shows "improving efficacy results," the company said. The results were presented as a poster short talk at the 2020 American Society of Clinical Oncology Virtual Annual Meeting. TACTI-002 is being conducted in collaboration with Merck (MRK). The study is evaluating the combination of the company's lead product candidate eftilagimod alpha with Merck's KEYTRUDA in up to 109 patients with second line Head and Neck Squamous Cell Carcinoma or Non-Small Cell Lung Cancer in first and second line. Immutep CSO and CMO, Frederic Triebel said: "TACTI-002 is generating increasingly promising data from both the NSCLC and HNSCC arms of study, as patients continue to receive efti in combination with KEYTRUDA. Remarkably, one HNSCC patient has even achieved a complete response, bringing the total response rate to an improved 39% in this arm. This is an early indication that the efti in combination with pembrolizumab may more than double the proportion of HNSCC patients that respond to pembrolizumab monotherapy, which is usually 18% or less1."

ShowHide Related Items >><<
MRK Merck
$80.85 /

+1.83 (+2.32%)

IMMP Immutep
$1.25 /

+0.005 (+0.40%)

IMMP Immutep
$1.25 /

+0.005 (+0.40%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
MRK Merck
$80.85 /

+1.83 (+2.32%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

Conference/Events
American Society of Clinical Oncology (ASCO) to hold virtual meeting » 04:55
05/31/20
05/31
04:55
05/31/20
04:55
ABBV

AbbVie

$92.78 /

+2.77 (+3.08%)

, ALLO

Allogene Therapeutics

$48.08 /

+1.48 (+3.18%)

, AMGN

Amgen

$230.13 /

+6.11 (+2.73%)

, ATNX

Athenex

$10.91 /

-0.21 (-1.89%)

, AVEO

Aveo Pharmaceuticals

$8.14 /

-1.08 (-11.71%)

, AZN

AstraZeneca

$54.60 /

+1.1 (+2.06%)

, BCYC

Bicycle Therapeutics

$17.50 /

-0.785 (-4.29%)

, BLUE

Bluebird Bio

$63.63 /

+2.82 (+4.64%)

, BPMC

Blueprint Medicines

$65.16 /

-1.84 (-2.75%)

, CGEN

Compugen

$15.50 /

+3.13 (+25.30%)

, HALO

Halozyme

$24.26 /

+0.79 (+3.37%)

, EXEL

Exelixis

$24.68 /

+0.35 (+1.44%)

, DCPH

Deciphera

$58.47 /

+1.53 (+2.69%)

, KURA

Kura Oncology

$17.09 /

+0.38 (+2.27%)

, KPTI

Karyopharm

$18.49 /

-0.31 (-1.65%)

, MRK

Merck

$80.85 /

+1.83 (+2.32%)

, BMY

Bristol-Myers

$59.72 /

-0.08 (-0.13%)

, MRSN

Mersana Therapeutics

$22.55 /

+2.85 (+14.47%)

, NXTC

NextCure

$31.20 /

-1.96 (-5.91%)

, PFE

Pfizer

$38.14 /

-0.03 (-0.08%)

, RECN

Changed to RGP

$0.00 /

+ (+0.00%)

, REPL

Replimune Group

$18.85 /

+0.3 (+1.62%)

, SBPH

Spring Bank Pharmaceuticals

$1.66 /

+0.015 (+0.91%)

, SGEN

Seattle Genetics

$157.30 /

+5.53 (+3.64%)

, STML

Stemline

$11.89 /

+ (+0.00%)

, SYRS

Syros Pharmaceuticals

$9.77 /

+0.25 (+2.63%)

, TRIL

Trillium Therapeutics

$6.76 /

+0.995 (+17.26%)

, TROV

Changed name to CRDF

$0.00 /

+ (+0.00%)

, XNCR

Xencor

$30.30 /

-0.69 (-2.23%)

Virtual Annual Meeting of…

Virtual Annual Meeting of ASCO 2020 will be held on May 29-31. Webcast Link

ShowHide Related Items >><<
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

NXTC NextCure
$31.20 /

-1.96 (-5.91%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

CGEN Compugen
$15.50 /

+3.13 (+25.30%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

05/22/20 Piper Sandler
Growth of Biohaven's Nurtec continues to beat AbbVie's Ubrelvy, says Piper
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
05/18/20 BofA
AbbVie reinstated with a Neutral at BofA
05/12/20 JPMorgan
AbbVie resumed with an Overweight from Neutral at JPMorgan
ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

05/29/20 H.C. Wainwright
Allogene Therapeutics price target raised to $55 from $42 at H.C. Wainwright
05/29/20 Piper Sandler
Allogene Therapeutics price target raised to $70 from $50 at Piper Sandler
05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy with $60 target at Roth Capital
05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy from Neutral at Roth Capital
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
ATNX Athenex
$10.91 /

-0.21 (-1.89%)

12/13/19 RBC Capital
Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital
12/06/19 SunTrust
Athenex initiated with a Buy at SunTrust
11/19/19 RBC Capital
Athenex gets 'third SABCS win' ahead of meeting, says RBC Capital
08/07/19 RBC Capital
Athenex's Oraxol data 'near best-case,' says RBC Capital
AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

05/29/20 Piper Sandler
Aveo Pharmaceuticals price target raised to $26 from $18.50 at Piper Sandler
05/29/20 Baird
Aveo Pharmaceuticals price target raised to $24 from $15 at Baird
05/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $10 from $6 at H.C. Wainwright
04/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright
AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

05/29/20 Guggenheim
AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim
05/14/20 Evercore ISI
Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine
05/06/20 Morgan Stanley
AstraZeneca price target raised to 8,630 GBp from 8,600 GBp at Morgan Stanley
05/04/20 Citi
Citi opens 'positive catalyst watch' on AstraZeneca
BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
04/07/20 Piper Sandler
Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler
02/25/20 Piper Sandler
Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler
BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
05/12/20 RBC Capital
Bluebird Bio initiated with an Outperform at RBC Capital
05/12/20 Oppenheimer
Bluebird Bio price target lowered to $111 from $122 at Oppenheimer
BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

05/29/20 Raymond James
Blueprint approval for pralsetinib could come before PDUFA, says Raymond James
05/06/20 Nomura Instinet
Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet
05/05/20 Barclays
Blueprint Medicines initiated with an Equal Weight at Barclays
04/29/20 SVB Leerink
Deciphera price target raised to $55 from $50 at SVB Leerink
CGEN Compugen
$15.50 /

+3.13 (+25.30%)

05/26/20 JMP Securities
Compugen resumed with an Outperform at JMP Securities
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 Stifel
Compugen initiated with a Buy at Stifel
05/07/20
Fly Intel: Top five analyst initiations
HALO Halozyme
$24.26 /

+0.79 (+3.37%)

05/26/20 Piper Sandler
Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler
05/12/20 JMP Securities
Halozyme price target raised to $34 from $24 at JMP Securities
05/04/20 Cantor Fitzgerald
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

05/18/20 SunTrust
Deciphera price target raised to $91 from $82 at SunTrust
05/18/20 Barclays
Deciphera price target raised to $85 from $80 at Barclays
05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
05/15/20 Piper Sandler
Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler
KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
05/06/20 Wedbush
Kura prioritizing development of tipifarnib for HRAS-HNSCC, says Wedbush
KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
MRK Merck
$80.85 /

+1.83 (+2.32%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

05/27/20 H.C. Wainwright
Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright
04/29/20 BTIG
Mersana Therapeutics initiated with a Buy at BTIG
01/21/20 H.C. Wainwright
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright
08/20/19 H.C. Wainwright
H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana
NXTC NextCure
$31.20 /

-1.96 (-5.91%)

05/29/20 Piper Sandler
NextCure data shows S15-mediated activity, says Piper Sandler
05/26/20 JMP Securities
NextCure initiated with an Outperform at JMP Securities
04/13/20 Piper Sandler
NextCure could report Phase I biomarker data at ASCO, says Piper Sandler
03/24/20 Benchmark
NextCure initiated with a Buy at Benchmark
PFE Pfizer
$38.14 /

-0.03 (-0.08%)

05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
RECN Changed to RGP
$0.00 /

+ (+0.00%)

01/03/20 Baird
Resources Connection Q3 guidance 'materially below' expectations, says Baird
10/03/19 JPMorgan
Resources Connection near-term outlook remains challenged, says JPMorgan
REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
09/04/19 Roth Capital
Replimune Group initiated with a Buy at Roth Capital
SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

04/02/20 Piper Sandler
Piper Sandler keeps Neutral on Spring Bank as study enrollment expected to slow
01/29/20 Jefferies
Spring Bank Pharmaceuticals downgraded to Hold from Buy at Jefferies
01/29/20 Piper Sandler
Piper keeps Neutral rating on Spring Bank after inarigivir discontinued
12/30/19
Fly Intel: Top five analyst actions
SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 JMP Securities
Seattle Genetics initiated with an Outperform at JMP Securities
05/26/20 Goldman Sachs
Incyte downgraded to Buy from Conviction Buy at Goldman Sachs
05/26/20 Goldman Sachs
Seattle Genetics upgraded to Conviction Buy from Buy at Goldman Sachs
STML Stemline
$11.89 /

+ (+0.00%)

05/05/20 H.C. Wainwright
Stemline downgraded to Neutral from Buy at H.C. Wainwright
05/05/20 Ladenburg
Stemline downgraded to Neutral from Buy at Ladenburg
05/04/20 Alliance Global Partners
Stemline downgraded to Neutral from Buy at Alliance Global Partners
05/04/20 Wedbush
Stemline downgraded to Neutral from Outperform at Wedbush
SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

05/29/20 Roth Capital
Syros Pharmaceuticals ASCO update bodes well for ph1 data, says Roth Capital
05/29/20 Piper Sandler
Syros price target raised to $14 after ASCO update at Piper Sandler
04/23/20 JonesTrading
Syros Pharmaceuticals initiated with a Buy at JonesTrading
03/06/20 H.C. Wainwright
Syros Pharmaceuticals price target lowered to $8 from $10 at H.C. Wainwright
TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

05/26/20 JMP Securities
Trillium Therapeutics initiated with an Outperform at JMP Securities
08/19/19
Fly Intel: Top five analyst downgrades
08/19/19 H.C. Wainwright
Trillium Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

01/28/20 Noble Capital
Trovagene resumed with an Outperform at Noble Capital
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
02/25/20 Guggenheim
Xencor upgraded to Buy from Neutral at Guggenheim
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

NXTC NextCure
$31.20 /

-1.96 (-5.91%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

CGEN Compugen
$15.50 /

+3.13 (+25.30%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

XNCR Xencor
$30.30 /

-0.69 (-2.23%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

Saturday
Conference/Events
American Society of Clinical Oncology (ASCO) to hold virtual meeting » 04:55
05/30/20
05/30
04:55
05/30/20
04:55
ABBV

AbbVie

$92.78 /

+2.77 (+3.08%)

, ALLO

Allogene Therapeutics

$48.08 /

+1.48 (+3.18%)

, AMGN

Amgen

$230.13 /

+6.11 (+2.73%)

, ATNX

Athenex

$10.91 /

-0.21 (-1.89%)

, AVEO

Aveo Pharmaceuticals

$8.14 /

-1.08 (-11.71%)

, AZN

AstraZeneca

$54.60 /

+1.1 (+2.06%)

, BCYC

Bicycle Therapeutics

$17.50 /

-0.785 (-4.29%)

, BLUE

Bluebird Bio

$63.63 /

+2.82 (+4.64%)

, BPMC

Blueprint Medicines

$65.16 /

-1.84 (-2.75%)

, CGEN

Compugen

$15.50 /

+3.13 (+25.30%)

, HALO

Halozyme

$24.26 /

+0.79 (+3.37%)

, EXEL

Exelixis

$24.68 /

+0.35 (+1.44%)

, DCPH

Deciphera

$58.47 /

+1.53 (+2.69%)

, KURA

Kura Oncology

$17.09 /

+0.38 (+2.27%)

, KPTI

Karyopharm

$18.49 /

-0.31 (-1.65%)

, MRK

Merck

$80.85 /

+1.83 (+2.32%)

, BMY

Bristol-Myers

$59.72 /

-0.08 (-0.13%)

, MRSN

Mersana Therapeutics

$22.55 /

+2.85 (+14.47%)

, NXTC

NextCure

$31.20 /

-1.96 (-5.91%)

, PFE

Pfizer

$38.14 /

-0.03 (-0.08%)

, RECN

Changed to RGP

$0.00 /

+ (+0.00%)

, REPL

Replimune Group

$18.85 /

+0.3 (+1.62%)

, SBPH

Spring Bank Pharmaceuticals

$1.66 /

+0.015 (+0.91%)

, SGEN

Seattle Genetics

$157.30 /

+5.53 (+3.64%)

, STML

Stemline

$11.89 /

+ (+0.00%)

, SYRS

Syros Pharmaceuticals

$9.77 /

+0.25 (+2.63%)

, TRIL

Trillium Therapeutics

$6.76 /

+0.995 (+17.26%)

, TROV

Changed name to CRDF

$0.00 /

+ (+0.00%)

, XNCR

Xencor

$30.30 /

-0.69 (-2.23%)

Virtual Annual Meeting of…

Virtual Annual Meeting of ASCO 2020 will be held on May 29-31. Webcast Link

ShowHide Related Items >><<
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

NXTC NextCure
$31.20 /

-1.96 (-5.91%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

CGEN Compugen
$15.50 /

+3.13 (+25.30%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

05/22/20 Piper Sandler
Growth of Biohaven's Nurtec continues to beat AbbVie's Ubrelvy, says Piper
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
05/18/20 BofA
AbbVie reinstated with a Neutral at BofA
05/12/20 JPMorgan
AbbVie resumed with an Overweight from Neutral at JPMorgan
ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

05/29/20 H.C. Wainwright
Allogene Therapeutics price target raised to $55 from $42 at H.C. Wainwright
05/29/20 Piper Sandler
Allogene Therapeutics price target raised to $70 from $50 at Piper Sandler
05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy with $60 target at Roth Capital
05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy from Neutral at Roth Capital
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
ATNX Athenex
$10.91 /

-0.21 (-1.89%)

12/13/19 RBC Capital
Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital
12/06/19 SunTrust
Athenex initiated with a Buy at SunTrust
11/19/19 RBC Capital
Athenex gets 'third SABCS win' ahead of meeting, says RBC Capital
08/07/19 RBC Capital
Athenex's Oraxol data 'near best-case,' says RBC Capital
AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

05/29/20 Piper Sandler
Aveo Pharmaceuticals price target raised to $26 from $18.50 at Piper Sandler
05/29/20 Baird
Aveo Pharmaceuticals price target raised to $24 from $15 at Baird
05/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $10 from $6 at H.C. Wainwright
04/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright
AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

05/29/20 Guggenheim
AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim
05/14/20 Evercore ISI
Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine
05/06/20 Morgan Stanley
AstraZeneca price target raised to 8,630 GBp from 8,600 GBp at Morgan Stanley
05/04/20 Citi
Citi opens 'positive catalyst watch' on AstraZeneca
BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
04/07/20 Piper Sandler
Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler
02/25/20 Piper Sandler
Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler
BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
05/12/20 RBC Capital
Bluebird Bio initiated with an Outperform at RBC Capital
05/12/20 Oppenheimer
Bluebird Bio price target lowered to $111 from $122 at Oppenheimer
BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

05/29/20 Raymond James
Blueprint approval for pralsetinib could come before PDUFA, says Raymond James
05/06/20 Nomura Instinet
Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet
05/05/20 Barclays
Blueprint Medicines initiated with an Equal Weight at Barclays
04/29/20 SVB Leerink
Deciphera price target raised to $55 from $50 at SVB Leerink
CGEN Compugen
$15.50 /

+3.13 (+25.30%)

05/26/20 JMP Securities
Compugen resumed with an Outperform at JMP Securities
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 Stifel
Compugen initiated with a Buy at Stifel
05/07/20
Fly Intel: Top five analyst initiations
HALO Halozyme
$24.26 /

+0.79 (+3.37%)

05/26/20 Piper Sandler
Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler
05/12/20 JMP Securities
Halozyme price target raised to $34 from $24 at JMP Securities
05/04/20 Cantor Fitzgerald
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

05/18/20 SunTrust
Deciphera price target raised to $91 from $82 at SunTrust
05/18/20 Barclays
Deciphera price target raised to $85 from $80 at Barclays
05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
05/15/20 Piper Sandler
Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler
KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
05/06/20 Wedbush
Kura prioritizing development of tipifarnib for HRAS-HNSCC, says Wedbush
KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
MRK Merck
$80.85 /

+1.83 (+2.32%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

05/27/20 H.C. Wainwright
Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright
04/29/20 BTIG
Mersana Therapeutics initiated with a Buy at BTIG
01/21/20 H.C. Wainwright
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright
08/20/19 H.C. Wainwright
H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana
NXTC NextCure
$31.20 /

-1.96 (-5.91%)

05/29/20 Piper Sandler
NextCure data shows S15-mediated activity, says Piper Sandler
05/26/20 JMP Securities
NextCure initiated with an Outperform at JMP Securities
04/13/20 Piper Sandler
NextCure could report Phase I biomarker data at ASCO, says Piper Sandler
03/24/20 Benchmark
NextCure initiated with a Buy at Benchmark
PFE Pfizer
$38.14 /

-0.03 (-0.08%)

05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
RECN Changed to RGP
$0.00 /

+ (+0.00%)

01/03/20 Baird
Resources Connection Q3 guidance 'materially below' expectations, says Baird
10/03/19 JPMorgan
Resources Connection near-term outlook remains challenged, says JPMorgan
REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
09/04/19 Roth Capital
Replimune Group initiated with a Buy at Roth Capital
SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

04/02/20 Piper Sandler
Piper Sandler keeps Neutral on Spring Bank as study enrollment expected to slow
01/29/20 Jefferies
Spring Bank Pharmaceuticals downgraded to Hold from Buy at Jefferies
01/29/20 Piper Sandler
Piper keeps Neutral rating on Spring Bank after inarigivir discontinued
12/30/19
Fly Intel: Top five analyst actions
SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 JMP Securities
Seattle Genetics initiated with an Outperform at JMP Securities
05/26/20 Goldman Sachs
Incyte downgraded to Buy from Conviction Buy at Goldman Sachs
05/26/20 Goldman Sachs
Seattle Genetics upgraded to Conviction Buy from Buy at Goldman Sachs
STML Stemline
$11.89 /

+ (+0.00%)

05/05/20 H.C. Wainwright
Stemline downgraded to Neutral from Buy at H.C. Wainwright
05/05/20 Ladenburg
Stemline downgraded to Neutral from Buy at Ladenburg
05/04/20 Alliance Global Partners
Stemline downgraded to Neutral from Buy at Alliance Global Partners
05/04/20 Wedbush
Stemline downgraded to Neutral from Outperform at Wedbush
SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

05/29/20 Roth Capital
Syros Pharmaceuticals ASCO update bodes well for ph1 data, says Roth Capital
05/29/20 Piper Sandler
Syros price target raised to $14 after ASCO update at Piper Sandler
04/23/20 JonesTrading
Syros Pharmaceuticals initiated with a Buy at JonesTrading
03/06/20 H.C. Wainwright
Syros Pharmaceuticals price target lowered to $8 from $10 at H.C. Wainwright
TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

05/26/20 JMP Securities
Trillium Therapeutics initiated with an Outperform at JMP Securities
08/19/19
Fly Intel: Top five analyst downgrades
08/19/19 H.C. Wainwright
Trillium Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

01/28/20 Noble Capital
Trovagene resumed with an Outperform at Noble Capital
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
02/25/20 Guggenheim
Xencor upgraded to Buy from Neutral at Guggenheim
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

NXTC NextCure
$31.20 /

-1.96 (-5.91%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

CGEN Compugen
$15.50 /

+3.13 (+25.30%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

  • 29
    May
TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

XNCR Xencor
$30.30 /

-0.69 (-2.23%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

Friday
Conference/Events
American Society of Clinical Oncology (ASCO) to hold virtual meeting » 10:14
05/29/20
05/29
10:14
05/29/20
10:14
ABBV

AbbVie

$90.97 /

+0.96 (+1.07%)

, ALLO

Allogene Therapeutics

$45.80 /

-0.8 (-1.72%)

, AMGN

Amgen

$224.10 /

+0.08 (+0.04%)

, ATNX

Athenex

$11.08 /

-0.04 (-0.36%)

, AVEO

Aveo Pharmaceuticals

$8.01 /

-1.21 (-13.12%)

, AZN

AstraZeneca

$54.97 /

+1.47 (+2.75%)

, BCYC

Bicycle Therapeutics

$18.28 /

+ (+0.00%)

, BLUE

Bluebird Bio

$61.30 /

+0.49 (+0.81%)

, BPMC

Blueprint Medicines

$66.44 /

-0.56 (-0.84%)

, CGEN

Compugen

$12.92 /

+0.55 (+4.45%)

, HALO

Halozyme

$23.49 /

+0.02 (+0.09%)

, EXEL

Exelixis

$24.46 /

+0.13 (+0.53%)

, DCPH

Deciphera

$56.95 /

+0.01 (+0.02%)

, KURA

Kura Oncology

$17.10 /

+0.39 (+2.33%)

, KPTI

Karyopharm

$18.80 /

+ (+0.00%)

, MRK

Merck

$79.24 /

+0.22 (+0.28%)

, BMY

Bristol-Myers

$60.18 /

+0.38 (+0.64%)

, MRSN

Mersana Therapeutics

$20.50 /

+0.8 (+4.06%)

, NXTC

NextCure

$32.56 /

-0.6 (-1.81%)

, PFE

Pfizer

$38.06 /

-0.11 (-0.29%)

, RECN

Changed to RGP

$0.00 /

+ (+0.00%)

, REPL

Replimune Group

$18.41 /

-0.14 (-0.75%)

, SBPH

Spring Bank Pharmaceuticals

$1.56 /

-0.085 (-5.17%)

, SGEN

Seattle Genetics

$154.34 /

+2.57 (+1.69%)

, STML

Stemline

$11.88 /

-0.01 (-0.08%)

, SYRS

Syros Pharmaceuticals

$9.43 /

-0.09 (-0.95%)

, TRIL

Trillium Therapeutics

$6.20 /

+0.435 (+7.55%)

, TROV

Changed name to CRDF

$0.00 /

+ (+0.00%)

, XNCR

Xencor

$30.45 /

-0.54 (-1.74%)

Virtual Annual Meeting of…

Virtual Annual Meeting of ASCO 2020 will be held on May 29-31. Webcast Link

ShowHide Related Items >><<
XNCR Xencor
$30.45 /

-0.54 (-1.74%)

TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

TRIL Trillium Therapeutics
$6.20 /

+0.435 (+7.55%)

SYRS Syros Pharmaceuticals
$9.43 /

-0.09 (-0.95%)

STML Stemline
$11.88 /

-0.01 (-0.08%)

SGEN Seattle Genetics
$154.34 /

+2.57 (+1.69%)

SBPH Spring Bank Pharmaceuticals
$1.56 /

-0.085 (-5.17%)

REPL Replimune Group
$18.41 /

-0.14 (-0.75%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.06 /

-0.11 (-0.29%)

NXTC NextCure
$32.56 /

-0.6 (-1.81%)

MRSN Mersana Therapeutics
$20.50 /

+0.8 (+4.06%)

MRK Merck
$79.24 /

+0.22 (+0.28%)

KURA Kura Oncology
$17.10 /

+0.39 (+2.33%)

KPTI Karyopharm
$18.80 /

+ (+0.00%)

HALO Halozyme
$23.49 /

+0.02 (+0.09%)

EXEL Exelixis
$24.46 /

+0.13 (+0.53%)

DCPH Deciphera
$56.95 /

+0.01 (+0.02%)

CGEN Compugen
$12.92 /

+0.55 (+4.45%)

BPMC Blueprint Medicines
$66.44 /

-0.56 (-0.84%)

BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

BLUE Bluebird Bio
$61.30 /

+0.49 (+0.81%)

BCYC Bicycle Therapeutics
$18.28 /

+ (+0.00%)

AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

AVEO Aveo Pharmaceuticals
$8.01 /

-1.21 (-13.12%)

ATNX Athenex
$11.08 /

-0.04 (-0.36%)

AMGN Amgen
$224.10 /

+0.08 (+0.04%)

ALLO Allogene Therapeutics
$45.80 /

-0.8 (-1.72%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

05/22/20 Piper Sandler
Growth of Biohaven's Nurtec continues to beat AbbVie's Ubrelvy, says Piper
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
05/18/20 BofA
AbbVie reinstated with a Neutral at BofA
05/12/20 JPMorgan
AbbVie resumed with an Overweight from Neutral at JPMorgan
ALLO Allogene Therapeutics
$45.80 /

-0.8 (-1.72%)

05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy with $60 target at Roth Capital
05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy from Neutral at Roth Capital
05/18/20 H.C. Wainwright
Precision BioSciences could have 'significant upside,' says H.C. Wainwright
05/15/20 Guggenheim
Guggenheim upgrades Allogene to Buy with $50 target after ASCO upside surprise
AMGN Amgen
$224.10 /

+0.08 (+0.04%)

05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
ATNX Athenex
$11.08 /

-0.04 (-0.36%)

12/13/19 RBC Capital
Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital
12/06/19 SunTrust
Athenex initiated with a Buy at SunTrust
11/19/19 RBC Capital
Athenex gets 'third SABCS win' ahead of meeting, says RBC Capital
08/07/19 RBC Capital
Athenex's Oraxol data 'near best-case,' says RBC Capital
AVEO Aveo Pharmaceuticals
$8.01 /

-1.21 (-13.12%)

05/29/20 Baird
Aveo Pharmaceuticals price target raised to $24 from $15 at Baird
05/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $10 from $6 at H.C. Wainwright
04/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright
03/31/20 Piper Sandler
Aveo Pharmaceuticals price target lowered to $18.50 from $20 at Piper Sandler
AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

05/29/20 Guggenheim
AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim
05/14/20 Evercore ISI
Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine
05/06/20 Morgan Stanley
AstraZeneca price target raised to 8,630 GBp from 8,600 GBp at Morgan Stanley
05/04/20 Citi
Citi opens 'positive catalyst watch' on AstraZeneca
BCYC Bicycle Therapeutics
$18.28 /

+ (+0.00%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
04/07/20 Piper Sandler
Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler
02/25/20 Piper Sandler
Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler
BLUE Bluebird Bio
$61.30 /

+0.49 (+0.81%)

05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
05/12/20 RBC Capital
Bluebird Bio initiated with an Outperform at RBC Capital
05/12/20 Oppenheimer
Bluebird Bio price target lowered to $111 from $122 at Oppenheimer
BPMC Blueprint Medicines
$66.44 /

-0.56 (-0.84%)

05/06/20 Nomura Instinet
Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet
05/05/20 Barclays
Blueprint Medicines initiated with an Equal Weight at Barclays
04/29/20 SVB Leerink
Deciphera price target raised to $55 from $50 at SVB Leerink
04/29/20 SVB Leerink
Blueprint Medicines price target lowered to $105 from $125 at SVB Leerink
CGEN Compugen
$12.92 /

+0.55 (+4.45%)

05/26/20 JMP Securities
Compugen resumed with an Outperform at JMP Securities
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 Stifel
Compugen initiated with a Buy at Stifel
05/07/20
Fly Intel: Top five analyst initiations
HALO Halozyme
$23.49 /

+0.02 (+0.09%)

05/26/20 Piper Sandler
Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler
05/12/20 JMP Securities
Halozyme price target raised to $34 from $24 at JMP Securities
05/04/20 Cantor Fitzgerald
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
EXEL Exelixis
$24.46 /

+0.13 (+0.53%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
DCPH Deciphera
$56.95 /

+0.01 (+0.02%)

05/18/20 SunTrust
Deciphera price target raised to $91 from $82 at SunTrust
05/18/20 Barclays
Deciphera price target raised to $85 from $80 at Barclays
05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
05/15/20 Piper Sandler
Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler
KURA Kura Oncology
$17.10 /

+0.39 (+2.33%)

05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
05/06/20 Wedbush
Kura prioritizing development of tipifarnib for HRAS-HNSCC, says Wedbush
05/05/20 H.C. Wainwright
Kura Oncology price target lowered to $22 from $29 at H.C. Wainwright
05/05/20 Barclays
Kura Oncology initiated with an Overweight at Barclays
KPTI Karyopharm
$18.80 /

+ (+0.00%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
MRK Merck
$79.24 /

+0.22 (+0.28%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
MRSN Mersana Therapeutics
$20.50 /

+0.8 (+4.06%)

05/27/20 H.C. Wainwright
Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright
04/29/20 BTIG
Mersana Therapeutics initiated with a Buy at BTIG
01/21/20 H.C. Wainwright
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright
08/20/19 H.C. Wainwright
H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana
NXTC NextCure
$32.56 /

-0.6 (-1.81%)

05/26/20 JMP Securities
NextCure initiated with an Outperform at JMP Securities
04/13/20 Piper Sandler
NextCure could report Phase I biomarker data at ASCO, says Piper Sandler
03/24/20 Benchmark
NextCure initiated with a Buy at Benchmark
03/02/20 Roth Capital
NextCure initiated with a Buy at Roth Capital
PFE Pfizer
$38.06 /

-0.11 (-0.29%)

05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
RECN Changed to RGP
$0.00 /

+ (+0.00%)

01/03/20 Baird
Resources Connection Q3 guidance 'materially below' expectations, says Baird
10/03/19 JPMorgan
Resources Connection near-term outlook remains challenged, says JPMorgan
REPL Replimune Group
$18.41 /

-0.14 (-0.75%)

05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
09/04/19 Roth Capital
Replimune Group initiated with a Buy at Roth Capital
SBPH Spring Bank Pharmaceuticals
$1.56 /

-0.085 (-5.17%)

04/02/20 Piper Sandler
Piper Sandler keeps Neutral on Spring Bank as study enrollment expected to slow
01/29/20 Jefferies
Spring Bank Pharmaceuticals downgraded to Hold from Buy at Jefferies
01/29/20 Piper Sandler
Piper keeps Neutral rating on Spring Bank after inarigivir discontinued
12/30/19
Fly Intel: Top five analyst actions
SGEN Seattle Genetics
$154.34 /

+2.57 (+1.69%)

05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 JMP Securities
Seattle Genetics initiated with an Outperform at JMP Securities
05/26/20 Goldman Sachs
Incyte downgraded to Buy from Conviction Buy at Goldman Sachs
05/26/20 Goldman Sachs
Seattle Genetics upgraded to Conviction Buy from Buy at Goldman Sachs
STML Stemline
$11.88 /

-0.01 (-0.08%)

05/05/20 H.C. Wainwright
Stemline downgraded to Neutral from Buy at H.C. Wainwright
05/05/20 Ladenburg
Stemline downgraded to Neutral from Buy at Ladenburg
05/04/20 Alliance Global Partners
Stemline downgraded to Neutral from Buy at Alliance Global Partners
05/04/20 Wedbush
Stemline downgraded to Neutral from Outperform at Wedbush
SYRS Syros Pharmaceuticals
$9.43 /

-0.09 (-0.95%)

04/23/20 JonesTrading
Syros Pharmaceuticals initiated with a Buy at JonesTrading
03/06/20 H.C. Wainwright
Syros Pharmaceuticals price target lowered to $8 from $10 at H.C. Wainwright
01/17/20 Wedbush
Syros Pharmaceuticals risk/reward balanced ahead of data readouts, says Wedbush
01/17/20 Wedbush
Syros Pharmaceuticals downgraded to Neutral from Outperform at Wedbush
TRIL Trillium Therapeutics
$6.20 /

+0.435 (+7.55%)

05/26/20 JMP Securities
Trillium Therapeutics initiated with an Outperform at JMP Securities
08/19/19
Fly Intel: Top five analyst downgrades
08/19/19 H.C. Wainwright
Trillium Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

01/28/20 Noble Capital
Trovagene resumed with an Outperform at Noble Capital
XNCR Xencor
$30.45 /

-0.54 (-1.74%)

05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
02/25/20 Guggenheim
Xencor upgraded to Buy from Neutral at Guggenheim
XNCR Xencor
$30.45 /

-0.54 (-1.74%)

TRIL Trillium Therapeutics
$6.20 /

+0.435 (+7.55%)

SYRS Syros Pharmaceuticals
$9.43 /

-0.09 (-0.95%)

STML Stemline
$11.88 /

-0.01 (-0.08%)

SGEN Seattle Genetics
$154.34 /

+2.57 (+1.69%)

SBPH Spring Bank Pharmaceuticals
$1.56 /

-0.085 (-5.17%)

REPL Replimune Group
$18.41 /

-0.14 (-0.75%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.06 /

-0.11 (-0.29%)

NXTC NextCure
$32.56 /

-0.6 (-1.81%)

MRSN Mersana Therapeutics
$20.50 /

+0.8 (+4.06%)

MRK Merck
$79.24 /

+0.22 (+0.28%)

KURA Kura Oncology
$17.10 /

+0.39 (+2.33%)

KPTI Karyopharm
$18.80 /

+ (+0.00%)

HALO Halozyme
$23.49 /

+0.02 (+0.09%)

EXEL Exelixis
$24.46 /

+0.13 (+0.53%)

DCPH Deciphera
$56.95 /

+0.01 (+0.02%)

CGEN Compugen
$12.92 /

+0.55 (+4.45%)

BPMC Blueprint Medicines
$66.44 /

-0.56 (-0.84%)

BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

BLUE Bluebird Bio
$61.30 /

+0.49 (+0.81%)

BCYC Bicycle Therapeutics
$18.28 /

+ (+0.00%)

AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

AVEO Aveo Pharmaceuticals
$8.01 /

-1.21 (-13.12%)

ATNX Athenex
$11.08 /

-0.04 (-0.36%)

AMGN Amgen
$224.10 /

+0.08 (+0.04%)

ALLO Allogene Therapeutics
$45.80 /

-0.8 (-1.72%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

  • 29
    May
TRIL Trillium Therapeutics
$6.20 /

+0.435 (+7.55%)

PFE Pfizer
$38.06 /

-0.11 (-0.29%)

MRK Merck
$79.24 /

+0.22 (+0.28%)

BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

AMGN Amgen
$224.10 /

+0.08 (+0.04%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

XNCR Xencor
$30.45 /

-0.54 (-1.74%)

STML Stemline
$11.88 /

-0.01 (-0.08%)

SGEN Seattle Genetics
$154.34 /

+2.57 (+1.69%)

SBPH Spring Bank Pharmaceuticals
$1.56 /

-0.085 (-5.17%)

PFE Pfizer
$38.06 /

-0.11 (-0.29%)

MRSN Mersana Therapeutics
$20.50 /

+0.8 (+4.06%)

MRK Merck
$79.24 /

+0.22 (+0.28%)

KPTI Karyopharm
$18.80 /

+ (+0.00%)

HALO Halozyme
$23.49 /

+0.02 (+0.09%)

EXEL Exelixis
$24.46 /

+0.13 (+0.53%)

DCPH Deciphera
$56.95 /

+0.01 (+0.02%)

BPMC Blueprint Medicines
$66.44 /

-0.56 (-0.84%)

BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

BLUE Bluebird Bio
$61.30 /

+0.49 (+0.81%)

BCYC Bicycle Therapeutics
$18.28 /

+ (+0.00%)

AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

AVEO Aveo Pharmaceuticals
$8.01 /

-1.21 (-13.12%)

ATNX Athenex
$11.08 /

-0.04 (-0.36%)

AMGN Amgen
$224.10 /

+0.08 (+0.04%)

ALLO Allogene Therapeutics
$45.80 /

-0.8 (-1.72%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

TRIL Trillium Therapeutics
$6.20 /

+0.435 (+7.55%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.06 /

-0.11 (-0.29%)

MRSN Mersana Therapeutics
$20.50 /

+0.8 (+4.06%)

MRK Merck
$79.24 /

+0.22 (+0.28%)

EXEL Exelixis
$24.46 /

+0.13 (+0.53%)

BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.